Cargando…

Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden

BACKGROUND: Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a heterogeneous disease with a clinical presentation that varies according to geographical area and TTR mutation. The symptoms of Val50Met-ATTRv are mainly neuropathic and progress to complete disability and death in most untreated pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	González-Moreno, Juan, Gaya-Barroso, Aina, Losada-López, Inés, Rodríguez, Adrián, Bosch-Rovira, Teresa, Ripoll-Vera, Tomás, Usón, Mercedes, Figuerola, Antoni, Descals, Cristina, Montalà, Carles, Ferrer-Nadal, María Asunción, Cisneros-Barroso, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191011/ https://www.ncbi.nlm.nih.gov/pubmed/34112225 http://dx.doi.org/10.1186/s13023-021-01910-5

Ejemplares similares

Accessibility to Occupational Therapy Services for Hereditary Transthyretin Amyloidosis
por: Gayà-Barroso, Aina, et al.
Publicado: (2022)

Occupational practice in patients with hereditary transthyretin amyloidosis, a qualitative study
por: Gayà-Barroso, Aina, et al.
Publicado: (2023)

Establishing Occupational Therapy Needs: A Semi-Structured Interview with Hereditary Transthyretin Amyloidosis Patients
por: Gayà-Barroso, Aina, et al.
Publicado: (2022)

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022)

Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families
por: Suhr, Ole Bernt, et al.
Publicado: (2019)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington-Cruz, Márcia, et al.
Publicado: (2021)

Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis
por: Anan, Intissar, et al.
Publicado: (2022)

Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2018)

Non‐Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis
por: Hirakawa, Kyoko, et al.
Publicado: (2018)

Long-term surgical results of trabeculectomy for secondary glaucoma in Val30Met hereditary transthyretin amyloidosis
por: Kitahara, Junya, et al.
Publicado: (2023)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis
por: Zampino, Serena, et al.
Publicado: (2023)

Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area
por: Wang, Shun, et al.
Publicado: (2022)

Suture trabeculotomy ab interno for secondary glaucoma in Japanese patients with Val30Met hereditary transthyretin amyloidosis
por: Kawaji, Takahiro, et al.
Publicado: (2022)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
por: Damy, Thibaud, et al.
Publicado: (2015)

Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca
por: Cisneros-Barroso, E., et al.
Publicado: (2023)

Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
por: Gundapaneni, B. K., et al.
Publicado: (2017)

The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant
por: Perfetto, Federico, et al.
Publicado: (2015)

A Novel Transthyretin Gene Mutation in Hereditary Transthyretin Amyloidosis: A Case Series of Met13dup Patients
por: Jeon, Kina, et al.
Publicado: (2023)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease
por: da Costa, Gonçalo, et al.
Publicado: (2015)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Hereditary transthyretin amyloidosis overview
por: Manganelli, Fiore, et al.
Publicado: (2020)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
por: Zou, Huizhen, et al.
Publicado: (2023)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
por: Yamaguchi, Hiroki, et al.
Publicado: (2022)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Recent advances in transthyretin amyloidosis therapy
por: Ueda, Mitsuharu, et al.
Publicado: (2014)

Molecular Tweezers Targeting Transthyretin Amyloidosis
por: Ferreira, Nelson, et al.
Publicado: (2014)

Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

A Late Diagnosis of Transthyretin Amyloidosis
por: Pfirman, Kristopher S, et al.
Publicado: (2022)

Modulation of the Mechanisms Driving Transthyretin Amyloidosis
por: Bezerra, Filipa, et al.
Publicado: (2020)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
por: Leedy, Douglas J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k9ihhq1du06r9oi1t30u9chtmd